These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 3812143)

  • 21. [What is the reason for the increase in beta-2-microglobulin levels in the blood when using cuprophane dialysis membranes?].
    Sulková S; Lapcík O; Votruba T
    Cas Lek Cesk; 1989 Apr; 128(17):520-3. PubMed ID: 2665936
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The influence of dialyzer geometry on blood coagulation and biocompatibility.
    Lins LE; Boberg U; Jacobson SH; Kjellstrand C; Ljungberg B; Skröder R
    Clin Nephrol; 1993 Nov; 40(5):281-5. PubMed ID: 8281717
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Research on dialyzers with improved biocompatibility.
    van der Steen A
    Clin Nephrol; 1986; 26 Suppl 1():S39-42. PubMed ID: 3829466
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Effect of hemodialysis on levels of parathormone in blood of patients with chronic kidney failure].
    Starzyk J; Kowalski D
    Wiad Lek; 1993 Apr; 46(7-8):283-5. PubMed ID: 8249416
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of uremia and hemodialysis on soluble L-selectin and leukocyte surface CD11b and L-selectin.
    Dou L; Brunet P; Dignat-George F; Sampol J; Berland Y
    Am J Kidney Dis; 1998 Jan; 31(1):67-73. PubMed ID: 9428454
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [The effect of hemodialysis with frequent use of cuprophan and polysulfone membranes on activation of complement in patients with chronic renal failure].
    Zukowska-Szczechowska E; Moczulski D; Grzeszczak W; Gosek K; Augustyn M; Staszewicz P
    Pol Arch Med Wewn; 1996 Nov; 96(5):458-68. PubMed ID: 9091856
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Evaluation of the biocompatibility of a new cellulose membrane by studying the complement system and histamine liberation].
    Tridon A; Deteix P; Coves G; Cluzel P; Marqués Verdier A; Wauquier JP; Bétail G; Baguet JC
    Nephrologie; 1987; 8(4):217-21. PubMed ID: 2447516
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Assembly of terminal SC5b-9 complement complexes: a new index of blood-membrane interaction.
    Schaefer RM; Rauterberg EW; Deppisch R; Vienken J
    Miner Electrolyte Metab; 1990; 16(1):73-6. PubMed ID: 2325595
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Beta 2-microglobulin kinetics during hemodialysis with different membranes].
    Stetsiuk EA; Siniukhin VN; Danilkov AP; Shpazhnikova NS; Nikolaeva NP; Khamaganova EG
    Urol Nefrol (Mosk); 1995; (3):18-20. PubMed ID: 7618215
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Effect of hemodialysis with cuprophane and polysulfone membranes on counts of leukocytes, granulocytes, monocytes, lymphocytes and lymphocyte subsets].
    Moczulski D; Zukowska-Szczechowska E; Grzeszczak W; Religa Z; Cichoń R; Szydłowska I
    Pol Arch Med Wewn; 1994 Nov; 92(5):400-7. PubMed ID: 7885988
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intradialytic body weight changes and dialyzer pore size as main contributing factors to the evolution of beta-2-microglobulin in dialysis.
    Vanholder RC; Ringoir SM
    Blood Purif; 1990; 8(1):32-44. PubMed ID: 2198890
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prospective crossover trial of the influence of vitamin E-coated dialyzer membranes on T-cell activation and cytokine induction.
    Girndt M; Lengler S; Kaul H; Sester U; Sester M; Köhler H
    Am J Kidney Dis; 2000 Jan; 35(1):95-104. PubMed ID: 10620550
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Biocompatibility and hemodynamic studies during polycarbonate versus cuprophane membrane dialysis.
    Schohn DC; Jahn HA; Eber M; Hauptmann G
    Blood Purif; 1986; 4(1-3):102-11. PubMed ID: 3730154
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The role of PAF and leukotrienes in bioincompatibility of cuprophane membranes in hemodialysis.
    Kabasakal C; Mir S; Gousseinov A; Cura A; Betin N; Coker I
    Turk J Pediatr; 1998; 40(3):413-20. PubMed ID: 9763906
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Normal T lymphocyte function in patients with end-stage renal disease hemodialyzed with 'high-flux' polysulfone membranes.
    Degiannis D; Czarnecki M; Donati D; Homer L; Eisinger RP; Raska K; Raskova J
    Am J Nephrol; 1990; 10(4):276-82. PubMed ID: 2240054
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Biocompatibility and performance of a modified cellulosic and a synthetic high flux dialyzer. A randomized crossover comparison between cellulose triacetate and polysulphon.
    Grooteman MP; Nubé MJ; van Limbeek J; van Houte AJ; Daha MR; van Geelen JA
    ASAIO J; 1995; 41(2):215-20. PubMed ID: 7640431
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lipid abnormalities in chronic renal failure patients undergoing hemodialysis.
    de Gómez Dumm NT; Giammona AM; Touceda LA; Raimondi C
    Medicina (B Aires); 2001; 61(2):142-6. PubMed ID: 11374135
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Biocompatibility aspects of dialyzer reprocessing: a comparison of 3 re-use methods and 3 membranes.
    Kuwahara T; Markert M; Wauters JP
    Clin Nephrol; 1989 Sep; 32(3):139-43. PubMed ID: 2791365
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Interaction between blood and dialysis membrane].
    Szepietowski T; Orłowski A
    Polim Med; 1991; 21(3-4):3-13. PubMed ID: 1822594
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Automatic re-utilization of capillary dialysis].
    Szepietowski T; Uzar J
    Polim Med; 1989; 19(3-4):107-18. PubMed ID: 2641400
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.